MovDisordV3, PascalFrancis, Corpus, bibRecord, 002353

Significance of non-presynaptic SPECT tracer methods in Parkinson's disease

Identifieur interne : 002353 ( PascalFrancis/Corpus ); précédent : 002352; suivant : 002354

Significance of non-presynaptic SPECT tracer methods in Parkinson's disease

Auteurs : Klaus L. Leenders

Source :

Movement disorders [ 0885-3185 ] ; 2003.

RBID : Pascal:04-0115295

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Tomographie émission positon, Tomoscintigraphie émission monophotonique, Produit diagnostic, Radioisotope, Récepteur dopaminergique D2, Débit sanguin régional, Diagnostic, Technique, Indication, Homme, HMPAO, IBZM.

English descriptors

KwdEn :
- D2 Dopamine receptor, Diagnosis, Diagnostic agent, Human, Indication, Parkinson disease, Positron emission tomography, Radioisotope, Regional blood flow, Single photon emission tomography, Technique.

Abstract

Tropane-related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D₂ receptors and HMPAO uptake is a measure of cerebral tissue perfusion.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 18`
A06				`@3 SUP7`
A08	`01`	`1`	`ENG`	`@1 Significance of non-presynaptic SPECT tracer methods in Parkinson's disease`
A09	`01`	`1`	`ENG`	`@1 Dopamine transporter imaging`
A11	`01`	`1`		`@1 LEENDERS (Klaus L.)`
A12	`01`	`1`		`@1 LEES (Andrew J.) @9 introd.`
A12	`02`	`1`		`@1 GROSSET (Donald G.) @9 ed.`
A14	`01`			`@1 Department of Neurology, Groningen University Hospital @2 Groningen @3 NLD @Z 1 aut.`
A15	`01`			`@1 Rita Lila Weston Institute of Neurological Studies @2 London @3 GBR @Z 1 aut.`
A15	`02`			`@1 Institute of Neurological Sciences @2 Glasgow @3 GBR @Z 2 aut.`
A20				`@2 S39-S42`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000113382420070`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 37 ref.`
A47	`01`	`1`		`@0 04-0115295`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Tropane-related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D₂ receptors and HMPAO uptake is a measure of cerebral tissue perfusion.
C02	`01`	`X`		`@0 002B24B07`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Tomographie émission positon @5 04`
C03	`02`	`X`	`ENG`	`@0 Positron emission tomography @5 04`
C03	`02`	`X`	`SPA`	`@0 Tomografía emisión positrones @5 04`
C03	`03`	`X`	`FRE`	`@0 Tomoscintigraphie émission monophotonique @5 05`
C03	`03`	`X`	`ENG`	`@0 Single photon emission tomography @5 05`
C03	`03`	`X`	`SPA`	`@0 Tomografía emisión fotón único @5 05`
C03	`04`	`X`	`FRE`	`@0 Produit diagnostic @5 07`
C03	`04`	`X`	`ENG`	`@0 Diagnostic agent @5 07`
C03	`04`	`X`	`SPA`	`@0 Producto diagnóstico @5 07`
C03	`05`	`X`	`FRE`	`@0 Radioisotope @5 08`
C03	`05`	`X`	`ENG`	`@0 Radioisotope @5 08`
C03	`05`	`X`	`SPA`	`@0 Radionúclido @5 08`
C03	`06`	`X`	`FRE`	`@0 Récepteur dopaminergique D2 @5 10`
C03	`06`	`X`	`ENG`	`@0 D2 Dopamine receptor @5 10 @6 «D2» Dopamine receptor`
C03	`06`	`X`	`SPA`	`@0 Receptor dopaminérgico D2 @5 10`
C03	`07`	`X`	`FRE`	`@0 Débit sanguin régional @5 13`
C03	`07`	`X`	`ENG`	`@0 Regional blood flow @5 13`
C03	`07`	`X`	`SPA`	`@0 Flujo sanguíneo regional @5 13`
C03	`08`	`X`	`FRE`	`@0 Diagnostic @5 17`
C03	`08`	`X`	`ENG`	`@0 Diagnosis @5 17`
C03	`08`	`X`	`SPA`	`@0 Diagnóstico @5 17`
C03	`09`	`X`	`FRE`	`@0 Technique @5 18`
C03	`09`	`X`	`ENG`	`@0 Technique @5 18`
C03	`09`	`X`	`SPA`	`@0 Técnica @5 18`
C03	`10`	`X`	`FRE`	`@0 Indication @5 19`
C03	`10`	`X`	`ENG`	`@0 Indication @5 19`
C03	`10`	`X`	`SPA`	`@0 Indicación @5 19`
C03	`11`	`X`	`FRE`	`@0 Homme @5 20`
C03	`11`	`X`	`ENG`	`@0 Human @5 20`
C03	`11`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`12`	`X`	`FRE`	`@0 HMPAO @4 INC @5 86`
C03	`13`	`X`	`FRE`	`@0 IBZM @4 INC @5 87`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Exploration radioisotopique @5 45`
C07	`06`	`X`	`ENG`	`@0 Radionuclide study @5 45`
C07	`06`	`X`	`SPA`	`@0 Exploración radioisotópica @5 45`
C07	`07`	`X`	`FRE`	`@0 Hémodynamique @5 69`
C07	`07`	`X`	`ENG`	`@0 Hemodynamics @5 69`
C07	`07`	`X`	`SPA`	`@0 Hemodinámica @5 69`
N21				`@1 075`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 04-0115295 INIST
ET :	Significance of non-presynaptic SPECT tracer methods in Parkinson's disease
AU :	LEENDERS (Klaus L.); LEES (Andrew J.); GROSSET (Donald G.)
AF :	Department of Neurology, Groningen University Hospital/Groningen/Pays-Bas (1 aut.); Rita Lila Weston Institute of Neurological Studies/London/Royaume-Uni (1 aut.); Institute of Neurological Sciences/Glasgow/Royaume-Uni (2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. SUP7; S39-S42; Bibl. 37 ref.
LA :	Anglais
EA :	Tropane-related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D₂ receptors and HMPAO uptake is a measure of cerebral tissue perfusion.
CC :	002B24B07; 002B17G
FD :	Parkinson maladie; Tomographie émission positon; Tomoscintigraphie émission monophotonique; Produit diagnostic; Radioisotope; Récepteur dopaminergique D2; Débit sanguin régional; Diagnostic; Technique; Indication; Homme; HMPAO; IBZM
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Exploration radioisotopique; Hémodynamique
ED :	Parkinson disease; Positron emission tomography; Single photon emission tomography; Diagnostic agent; Radioisotope; D2 Dopamine receptor; Regional blood flow; Diagnosis; Technique; Indication; Human
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Radionuclide study; Hemodynamics
SD :	Parkinson enfermedad; Tomografía emisión positrones; Tomografía emisión fotón único; Producto diagnóstico; Radionúclido; Receptor dopaminérgico D2; Flujo sanguíneo regional; Diagnóstico; Técnica; Indicación; Hombre
LO :	INIST-20953.354000113382420070
ID :	04-0115295

Links to Exploration step

Pascal:04-0115295

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Significance of non-presynaptic SPECT tracer methods in Parkinson's disease</title>
<author><name sortKey="Leenders, Klaus L" sort="Leenders, Klaus L" uniqKey="Leenders K" first="Klaus L." last="Leenders">Klaus L. Leenders</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Groningen University Hospital</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0115295</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0115295 INIST</idno>
<idno type="RBID">Pascal:04-0115295</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002353</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Significance of non-presynaptic SPECT tracer methods in Parkinson's disease</title>
<author><name sortKey="Leenders, Klaus L" sort="Leenders, Klaus L" uniqKey="Leenders K" first="Klaus L." last="Leenders">Klaus L. Leenders</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Groningen University Hospital</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>D2 Dopamine receptor</term>
<term>Diagnosis</term>
<term>Diagnostic agent</term>
<term>Human</term>
<term>Indication</term>
<term>Parkinson disease</term>
<term>Positron emission tomography</term>
<term>Radioisotope</term>
<term>Regional blood flow</term>
<term>Single photon emission tomography</term>
<term>Technique</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Tomographie émission positon</term>
<term>Tomoscintigraphie émission monophotonique</term>
<term>Produit diagnostic</term>
<term>Radioisotope</term>
<term>Récepteur dopaminergique D2</term>
<term>Débit sanguin régional</term>
<term>Diagnostic</term>
<term>Technique</term>
<term>Indication</term>
<term>Homme</term>
<term>HMPAO</term>
<term>IBZM</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Tropane-related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D<sub>2</sub>
 receptors and HMPAO uptake is a measure of cerebral tissue perfusion.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s3>SUP7</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Significance of non-presynaptic SPECT tracer methods in Parkinson's disease</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Dopamine transporter imaging</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>LEENDERS (Klaus L.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>LEES (Andrew J.)</s1>
<s9>introd.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>GROSSET (Donald G.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Department of Neurology, Groningen University Hospital</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Rita Lila Weston Institute of Neurological Studies</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Institute of Neurological Sciences</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s2>S39-S42</s2>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000113382420070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>37 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0115295</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Tropane-related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D<sub>2</sub>
 receptors and HMPAO uptake is a measure of cerebral tissue perfusion.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B24B07</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Tomographie émission positon</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Positron emission tomography</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tomografía emisión positrones</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Tomoscintigraphie émission monophotonique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Single photon emission tomography</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tomografía emisión fotón único</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Produit diagnostic</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Diagnostic agent</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Producto diagnóstico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Radioisotope</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Radioisotope</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Radionúclido</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>10</s5>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Débit sanguin régional</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Regional blood flow</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Flujo sanguíneo regional</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Diagnostic</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Diagnosis</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Diagnóstico</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Technique</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Technique</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Técnica</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Indication</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Indication</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Indicación</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>HMPAO</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>IBZM</s0>
<s4>INC</s4>
<s5>87</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Exploration radioisotopique</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Radionuclide study</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Exploración radioisotópica</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Hémodynamique</s0>
<s5>69</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Hemodynamics</s0>
<s5>69</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Hemodinámica</s0>
<s5>69</s5>
</fC07>
<fN21><s1>075</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0115295 INIST</NO>
<ET>Significance of non-presynaptic SPECT tracer methods in Parkinson's disease</ET>
<AU>LEENDERS (Klaus L.); LEES (Andrew J.); GROSSET (Donald G.)</AU>
<AF>Department of Neurology, Groningen University Hospital/Groningen/Pays-Bas (1 aut.); Rita Lila Weston Institute of Neurological Studies/London/Royaume-Uni (1 aut.); Institute of Neurological Sciences/Glasgow/Royaume-Uni (2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. SUP7; S39-S42; Bibl. 37 ref.</SO>
<LA>Anglais</LA>
<EA>Tropane-related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D<sub>2</sub>
 receptors and HMPAO uptake is a measure of cerebral tissue perfusion.</EA>
<CC>002B24B07; 002B17G</CC>
<FD>Parkinson maladie; Tomographie émission positon; Tomoscintigraphie émission monophotonique; Produit diagnostic; Radioisotope; Récepteur dopaminergique D2; Débit sanguin régional; Diagnostic; Technique; Indication; Homme; HMPAO; IBZM</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Exploration radioisotopique; Hémodynamique</FG>
<ED>Parkinson disease; Positron emission tomography; Single photon emission tomography; Diagnostic agent; Radioisotope; D2 Dopamine receptor; Regional blood flow; Diagnosis; Technique; Indication; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Radionuclide study; Hemodynamics</EG>
<SD>Parkinson enfermedad; Tomografía emisión positrones; Tomografía emisión fotón único; Producto diagnóstico; Radionúclido; Receptor dopaminérgico D2; Flujo sanguíneo regional; Diagnóstico; Técnica; Indicación; Hombre</SD>
<LO>INIST-20953.354000113382420070</LO>
<ID>04-0115295</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002353 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002353 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:04-0115295
   |texte=   Significance of non-presynaptic SPECT tracer methods in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Significance of non-presynaptic SPECT tracer methods in Parkinson's disease

Significance of non-presynaptic SPECT tracer methods in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri